Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer – final appraisal document

In DRAFT guidance, NICE recommends nivolumab for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy, only if the company provides it according to the commercial arrangement.

National Institute for Health and Care Excellence